Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioDelivery completes pain drug Phase 3 study
The study is designed to assess the efficacy and safety of BEMA Buprenorphine which is used to treat moderate to severe chronic pain. BDSI Product Development executive vice
The study is designed to assess the efficacy and safety of BEMA Buprenorphine which is used to treat moderate to severe chronic pain. BDSI Product Development executive vice
Menerba, an oral botanical, estrogen receptor beta (ER-b) selective drug is designed to treat vasomotor symptoms (hot flashes) associated with menopause. Menerba at doses far greater than the
Gammagard liquid is indicated as replacement therapy for primary humoral immunodeficiency in adult and pediatric patients two years of age or over. Baxter gammaglobulin trials medical director Richard
As per the terms of the deal, Prasco is responsible for marketing and distributing the Authorized Generic version of Ponstel, Mefenamic Acid Capsules, USP 250mg. Ponstel is a
Following this settlement, Lupin is now eligible for selling the generic versions of Solodyn in 45mg, 90mg, and 135mg strengths under a license from Medicis commencing November 2011,
Ranbaxy‘s Letrozole Tablets 2.5mg are the generic version of Novartis’ Femara which is approved for the adjuvant treatment of postmenopausal women with hormone receptor-positive early stage breast cancer.
Zydus’ Baddi manufacturing plant engaged in manufacturing oral solid dosage forms of drugs include hard gelatin capsules and tablets. Zydus Cadila chairman and managing director Pankaj Patel said
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has concluded that pioglitazone-containing medicines remain a valid treatment option for patients with type 2 diabetes. The CHMP
Based on company’s DOS47 technology, L-DOS47 is intended to function by leveraging a natural process in the body called the urea cycle to produce an anti-cancer effect. Th
The company is planning to develop some of its vaccines jointly with its partners from further financing round, which will be concluded by the end of 2011. CAP